RECRUITING

Duloxetine Metabolism and Fibromyalgia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

People with fibromyalgia report generalized body pain ("pain all over"), increased sensitivity to painful stimulation, chronic tiredness or low energy, sleep problems, and other physical and functional problems. The exact cause of the disorder is poorly understood, and treatment can be difficult. The degree to which duloxetine is helpful for people with fibromyalgia varies greatly. For some people, it is very helpful for managing fibromyalgia symptoms. For others, people may not notice any benefit. Yet for some, it is a little helpful and the effect is noticeable only when people forget to take the medicine. The purpose of this study is to collect data to better understand the relationship among gene types that control those enzymes, blood concentrations of duloxetine, and how it helps the symptoms.

Official Title

Duloxetine Metabolism and Fibromyalgia

Quick Facts

Study Start:2025-05-01
Study Completion:2026-05-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06866444

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults 18+
  2. * Meeting diagnostic criteria for Fibromyalgia
  3. * Patients taking Duloxetine 60 mg/day for at least 8 weeks
  1. * Pregnant patients per verbal confirmation
  2. * Patients that have a history of physician diagnosed kidney or liver disfunction or history of renal dialysis.
  3. * Patients requiring an interpreter to communicate
  4. * Patient's with progressive illnesses other than fibromyalgia that have a chronic pain and fatigue component (e.g., cancer patients receiving antineoplastic treatment, Parkinson's disease, Multiple Sclerosis).

Contacts and Locations

Study Contact

Jake Steenblick, DNP
CONTACT
801-585-1216
jacob.steenblik@nurs.utah.edu
Natalie R Bennion, MPH
CONTACT
801-585-7697
Natalie.Bennion@utah.edu

Principal Investigator

Jake Steenblick, DNP
PRINCIPAL_INVESTIGATOR
University of Utah

Study Locations (Sites)

Pain Management Center and Pain Research Center at the University of Utah
Salt Lake City, Utah, 84132
United States

Collaborators and Investigators

Sponsor: University of Utah

  • Jake Steenblick, DNP, PRINCIPAL_INVESTIGATOR, University of Utah

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-01
Study Completion Date2026-05-01

Study Record Updates

Study Start Date2025-05-01
Study Completion Date2026-05-01

Terms related to this study

Keywords Provided by Researchers

  • Duloxetine
  • Duloxetine metabolism

Additional Relevant MeSH Terms

  • Fibromyalgia
  • Duloxetine